Brian Slater

Brian Slater is a Life Sciences and IP partner and Co-Head of Sterlington’s Intellectual Property practice. He is a lead trial lawyer who has represented pharmaceutical, biotechnology and other technology innovators, including Gilead, Merck, Novartis, Regeneron, and Sanofi, in high-stakes intellectual property disputes.

He has extensive experience as lead counsel in high-value Hatch-Waxman patent litigations representing branded pharmaceutical companies against generic drug challengers, as well as bet-the-company patent cases involving biologics. Leveraging his litigation experience and deep industry knowledge, Brian also counsels emerging and established life sciences companies on protecting, licensing, and monetizing their IP assets.

Brian previously served as Chair of Life Sciences at Kramer Levin Naftalis & Frankel LLP. Before that, he spent over 20 years at the IP boutique, Fitzpatrick, Cella, Harper & Scinto (now Venable LLP), where he served on the management committee. He obtained his LL.M. from the University of Pennsylvania, where he was a Thouron Scholar.

Clients describe Brian as a “great decision maker” who is “brilliant on biosimilars” and “admired for his strategic nous and calm demeanor in pressurized litigation scenarios.” (IAM Patent 1000). He has been recognized, among others, as one of the Lawdragon’s “500 Leading Litigators in America,” as a “Patent Star” by Managing Intellectual Property, by Intellectual Asset Management “Patent 1000: The World’s Leading Patent Professionals,” and as a Life Sciences Lawyer by LMG Life Sciences.